New antibody therapy targets hard-to-treat ovarian cancer
Disease control
Recruiting now
This early-phase study tests a new drug called CTIM-76 in people with ovarian, testicular, or endometrial cancer that has come back or stopped responding to standard treatments. The drug works by helping the immune system attack cancer cells that have a specific marker called CLD…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated May 12, 2026 13:40 UTC